118 related articles for article (PubMed ID: 15453958)
41. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
42. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
[TBL] [Abstract][Full Text] [Related]
43. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
44. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.
Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ
J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613
[TBL] [Abstract][Full Text] [Related]
45. A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.
Bollineni VR; Kramer GM; Jansma EP; Liu Y; Oyen WJ
Eur J Cancer; 2016 Mar; 55():81-97. PubMed ID: 26820682
[TBL] [Abstract][Full Text] [Related]
46. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of
Vercellino L; Ouvrier MJ; Barré E; Cassinat B; de Beco V; Dosquet C; Chevret S; Meignin V; Chomienne C; Toubert ME; Merlet P; Kiladjian JJ
J Nucl Med; 2017 Oct; 58(10):1603-1608. PubMed ID: 28360204
[TBL] [Abstract][Full Text] [Related]
47. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
[TBL] [Abstract][Full Text] [Related]
48. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
Noy A; Schöder H; Gönen M; Weissler M; Ertelt K; Cohler C; Portlock C; Hamlin P; Yeung HW
Ann Oncol; 2009 Mar; 20(3):508-12. PubMed ID: 19139176
[TBL] [Abstract][Full Text] [Related]
49. 3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose.
McGuire SM; Menda Y; Boles Ponto LL; Gross B; Buatti J; Bayouth JE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):888-93. PubMed ID: 21300484
[TBL] [Abstract][Full Text] [Related]
50. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
Contractor KB; Kenny LM; Stebbing J; Rosso L; Ahmad R; Jacob J; Challapalli A; Turkheimer F; Al-Nahhas A; Sharma R; Coombes RC; Aboagye EO
Clin Cancer Res; 2011 Dec; 17(24):7664-72. PubMed ID: 22028493
[TBL] [Abstract][Full Text] [Related]
51. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
[TBL] [Abstract][Full Text] [Related]
52. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time.
Boles Ponto LL; Menda Y; Dornfeld K; Tewson TJ; Watkins GL; Sunderland J; Graham MM; Buatti J
Cancer Biother Radiopharm; 2010 Jun; 25(3):361-3. PubMed ID: 20578842
[TBL] [Abstract][Full Text] [Related]
53. Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer.
Shields AF; Lawhorn-Crews JM; Briston DA; Zalzala S; Gadgeel S; Douglas KA; Mangner TJ; Heilbrun LK; Muzik O
Clin Cancer Res; 2008 Jul; 14(14):4463-8. PubMed ID: 18628460
[TBL] [Abstract][Full Text] [Related]
54. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.
Chalkidou A; Landau DB; Odell EW; Cornelius VR; O'Doherty MJ; Marsden PK
Eur J Cancer; 2012 Dec; 48(18):3499-513. PubMed ID: 22658807
[TBL] [Abstract][Full Text] [Related]
55. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.
Menda Y; Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Gupta AK; Anderson C; McGuire S; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
Nucl Med Biol; 2010 May; 37(4):433-8. PubMed ID: 20447554
[TBL] [Abstract][Full Text] [Related]
56. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.
Buck AK; Schirrmeister H; Hetzel M; Von Der Heide M; Halter G; Glatting G; Mattfeldt T; Liewald F; Reske SN; Neumaier B
Cancer Res; 2002 Jun; 62(12):3331-4. PubMed ID: 12067968
[TBL] [Abstract][Full Text] [Related]
57. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
[TBL] [Abstract][Full Text] [Related]
58. [18F-fluorothymidine preclinical study in non-human primate. Dosimetry and biodistribution].
Valda A; Bastianello M; Casale G; Corradini H; Konowalik B; Nagle C; Manzur T; Riveros D; Gette G
Medicina (B Aires); 2022; 82(2):231-237. PubMed ID: 35417387
[TBL] [Abstract][Full Text] [Related]
59. Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer.
Kameyama R; Yamamoto Y; Izuishi K; Sano T; Nishiyama Y
Nucl Med Commun; 2011 Jun; 32(6):460-5. PubMed ID: 21423062
[TBL] [Abstract][Full Text] [Related]
60. [Evaluation of lesions of malignant lymphoma using histograms of regional SUV].
Ito S; Yamane T; Yoshiya K; Nagata T; Uchida H; Daimaru O; Kato K; Nishida K; Hashimoto H
Kaku Igaku; 2003 May; 40(2):175-84. PubMed ID: 12884784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
